Russia global vaccine ambitions stumble during supply shortage

This week, Guatemalan President Alejandro Giammattei said his country will seek to replace 8 million planned doses with supplies from other producers by the end of year after delays receiving its initial order.

Countries that embraced Sputnik amid a global rush to secure vaccines are increasingly reporting supply problems with the second component in the two-shot inoculation. In Argentina, a presidential adviser said the shortages put the government at risk as people were unable to receive the second dose within the recommended period of three months after the first.

President Vladimir Putin has touted Sputnik to leaders around the world as part of an ambitious Kremlin drive to put Russia on the map as a major player in the international vaccine business. But difficulties producing the promised shots could relegate it to a secondary-role as rivals from the U.S., Europe and China fill the gap.

"The developers designed their export plans around local production that vastly overestimated local capacity," said Samuel Ramani, a tutor of politics and international relations at Oxford University. "Russia has lost its head start as supplies from other countries became more available and now it's looking like an also-ran."

A spokesperson for the Russian Direct Investment Fund, the sovereign wealth fund that is responsible for Sputnik V's international marketing, said the existing contract with Guatemala was adjusted to a new delivery schedule and not canceled.

"Given the unprecedented worldwide demand all vaccine producers are experiencing some short-term supply issues," the RDIF representative said.

The fund said it still aims to produce enough to inoculate 700 million people outside Russia this year, a pledge its chief made in March. Airfinity, a London-based science analytics company, estimates 99 million doses have been delivered to date, with more than half of them for domestic use.

Kremlin spokesman Dmitry Peskov last week said delays in international Sputnik supplies were a result of the need to ramp up domestic vaccination as cases surged.

Putin hailed Sputnik as the first Covid-19 vaccine approved for use, a move criticized at the time as premature. However, it overcame initial questions about its effectiveness that emerged due to a lack of data, proving itself to be broadly on par with vaccines developed by western giants.

Unlike other Covid-19 vaccines, Sputnik's two shots are different. Production of the second has proved hard to scale up, according to buyers.

Supply delays for the second dose have slowed Sputnik V's roll-out in India, according to Erez Israeli, the chief executive of Dr Reddy's Laboratories Ltd., which is licensed to distribute the inoculation in that country. Indian producers have agreements to make as many as 850 million doses a year, although it's not clear when production will reach that level.

RDIF said its partners, including in India, are expected to scale up production in September to help reach the goal for this year.

In Argentina, a letter leaked last week exposed the government's frustration with slow Sputnik V supplies. On Wednesday, it announced an agreement with Pfizer for 20 million doses by year-end. Mexico has also reported delays.

In Brazil, governors from northeastern states who are trying to bring the vaccine said that 1.1 million doses that were expected for Wednesday were delayed by Russia, according to O Globo newspaper. Both parties are discussing a new schedule for the delivery, the paper said.

A shipment of 50,000 doses of the second component arrived in the Philippines this month several weeks after reports that people scheduled to receive the follow-up shot were facing delays.

Amid the hold-ups, RDIF said earlier this month the gap between shots can be safely extended to 180 days.

As Russia struggles to fulfill its commitments, Secretary of State Antony Blinken said Tuesday the U.S. delivered 1.5 million doses of the Moderna vaccine to Tajikistan, a former Soviet republic that Russia considers its strategic backyard. The announcement came as Russian Defense Minister Sergei Shoigu arrived in the capital of Dushanbe for talks.

Still, in Russia Sputnik V is presented as a success, helping extend its soft power and provide a quality, cost-effective alternative to vaccines produced in the West. Sputnik V has been approved for use in 69 countries and RDIF said last month it has deals to produce 1.6 billion doses this year.

"Sputnik V is a domestic propaganda victory," said Vasily Vlassov, an epidemiologist at Moscow's Higher School of Economics. "In the government and media, they dwell on its success getting approved in so many countries rather than the inconvenient details."